Esperion – The Lipid Management Company

Esperion is a pharmaceutical company that specializes in developing and commercializing non-statin, complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Bempedoic acid, the Company’s lead product candidate, is a targeted therapy that significantly reduces elevated LDL-C levels in patients with hypercholesterolemia, including those inadequately treated with current lipid-modifying therapies.

Esperion Leadership has Strong Industry Expertise in Cholesterol Biology

Esperion has assembled an innovative team of lipid management experts who is exclusively committed to leveraging its understanding of cholesterol biosynthesis. The team is focused on developing targeted, non-statin LDL-C lowering therapies to address patient needs that have the potential to make a substantial impact on lowering LDL-C and reducing the risk of global cardiovascular disease; the leading cause of death around the world.

Our Mission: Developing Innovative Lipid-Modifying Therapies

Esperion is passionately committed to introducing complementary, cost-effective, convenient LDL-C lowering therapies to patients with hypercholesterolemia and their physicians in the U.S. and around the world. Our therapies significantly reduce elevated levels of LDL-C in patients inadequately treated with current lipid-modifying therapies. Bempedoic acid, Esperion-discovered and developed, is a convenient, complementary and cost-effective targeted therapy that is “patient-friendly, physician-friendly, and payer-friendly”.